TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with episodic migraine at least 6 months before study~* at least 3 consecutive months of stable migraine headaches before study~* at least 4-14 headache days per month, of which 4-14 may be migraines~* must not have failed on more than 2 classes of migraine preventatives~Exclusion Criteria:~* previous use of the experimental device~* pregnant~* using more than 1 concurrent migraine preventive~* history of cardiovascular disease~* work night shifts~* diagnosed with vestibular migraine~* menstrual migraines exclusively~* diagnosed with post-traumatic migraine~* have a history of unstable mood or anxiety disorder~* use a hearing aid~* have a cochlear implant~* have chronic tinnitus~* have temporomandibular joint disease~* diagnosed with traumatic brain injury~* diagnosed with neurological disease other than headaches~* diagnosed vestibular and/or balance dysfunction~* history of abusing alcohol or other drugs~* are experiencing medication overuse headaches~* have had eye surgery in the previous 3 months~* have had ear surgery in the previous 6 months~* have active ear infections or a perforated tympanic membrane~* have participated in another clinical trial in the last 30 days~* are currently participating in another clinical trial~* using Botulinum toxin-based treatments for migraines or cosmetic reasons~* taking anti-emetics more than 2 times per week (consistently)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- active (Type: ACTIVE_COMPARATOR): active neuromodulation
- placebo (Type: PLACEBO_COMPARATOR): placebo neuromodulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV adenocarcinoma of the lung that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable disease by MRI or CT scan~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/dL~* No renal insufficiency~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart disease that would preclude study treatment~* No history of chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No lung disease that would preclude study treatment~* No serious lung disease (e.g., severe chronic obstructive pulmonary disease)~Neurologic:~* No neurological disease that would preclude study treatment~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No gastrointestinal or psychiatric disease that would preclude study treatment~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: How to Test Success of a Renal Denervation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male and female patients 18 years to 85 years of age, with a diagnosis of re-sistant hypertension (office sitting blood pressure \>140/90 mmHg and 24-hour blood pressure \>130/80 mmHg in patients treated with at least three antihypertensive drugs including a diuretic) and a clinical indication for a renal denervation.~Exclusion Criteria:~* Secondary cause of hypertension~* Anatomical contraindication to renal denervation (renal artery diameter less than 4 mm or more than 8 mm), multiple renal artery, length to bifurcation less than 2 cm~* Heart failure (normal ejection fractions on echocardiography and no clinical signs and symptoms of heart failure).~* Alcohol or drug abuse,~* Malignancy (unless healed or remission \> 5 years)~* Pregnancy~* Know allergy to contrast medium~* Participation in another study within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ultra-High-Resolution Mapping Guided Partial Antral Ablation for AF

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age over 20 years old and under 80 years old~2. Patients with non-valvular paroxysmal atrial fibrillation~3. Patients having atrial fibrillation even after receiving continued treatment with at least 1 antiarrhythmic drug for more than 6 weeks~4. Patients who could have informed consent~5. Patients who are available for a follow-up of more than at least three months after the catheter ablation~Exclusion Criteria:~1. Patients unsuitable for catheter ablation due to a previous history of pulmonary surgery or structural heart disease~2. Patients who cannot receive standard treatments such as anticoagulation therapy needed before the radiofrequency catheter ablation~3. Patients in the subject group vulnerable to a clinical study~4. Patients who had undergone a prior catheter ablation for atrial fibrillation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PVI using Ultra-High-Resolution Mapping (Type: None): The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Capable of giving informed consent~* Diagnosed with NAFLD as defined by the American Association for the Study of Liver Diseases (AASLD) who are treated or seen solely at the outpatient clinic at the Department of Hepatology at 400 Community Drive in Manhasset NY~Exclusion Criteria:~* Cirrhosis~* Absence of secondary causes of hepatic fat accumulation including:~* Excessive alcohol consumption~* Hepatitis C~* Wilson's Disease~* Lipodystrophy~* Starvation~* Parenteral Nutrition~* Abetalipoproteinemia~* Specific Medications: Amiodarone, Methotrexate, Tamoxifen, Corticosteroids, Valproate, Anti-retroviral agents)~* Reye's Syndrome~* HELLP Syndrome~* Inborn errors of metabolism (LCAT deficiency, cholesterol ester storage disease, Wolman disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotic administration (Type: EXPERIMENTAL): After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Technology-Based Intervention on Weight Change Post-Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18-60 years.~* 1-year post-bariatric surgery.~* Able to walk at 3 miles per hour during a cardiorespiratory fitness test.~Exclusion Criteria:~* Reports not having access to a computer, access to the Internet, email, or the availability to download software onto a computer.~* Reports not having a smart phone device that is compatible with the Jawbone UP3 System that will be examined in this study.~* Has a physical limitation that would prevent engaging in physical activity.~* Reports being treated for a current medical condition that could affect body weigh (diabetes mellitus, cancer, chronic renal insufficiency, hyperthyroidism, hypothyroidism, chronic liver disease).~* Reports current congestive failure, angina, uncontrolled arrhythmia, symptoms indicative of increased risk of an acute cardiovascular event, coronary artery bypass grafting or angioplasty, prior myocardial infarction, and conditions requiring anticoagulation therapy (deep vein thrombosis).~* Has a resting systolic blood pressure ≥ 150 mmHg or resting diastolic blood pressure of ≥100 mmHg or taking medication to control blood pressure that affects heart rate.~* Reports being treated for a psychological issue (i.e., depression, bipolar disorder, etc).~* Taking prescription or over-the-counter medications that affect body weight and metabolism.~* Currently participating in an exercise or weight control study or a current participant in a commercial weight reduction program.~* Currently being treated for an eating disorder.~* Currently pregnant, pregnant in the last 6 months, breast feeding in the last 3 months, lactating, to planning on becoming pregnant in the next 6 months.~* Planning on relocating outside of the greater Pittsburgh area within the next 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Standard Care (Type: ACTIVE_COMPARATOR): Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
- Technology-based Intervention (TECH) (Type: EXPERIMENTAL): TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Trial of a Therapeutic Platelet Transfusion Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia in complete remission~Exclusion Criteria:~* plasmatic coagulopathy~* history of severe bleeding complications in chemotherapy induced thrombocytopenia~* no increment in platelets after platelet transfusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Girls ages 13 to 17~* Tanner IV or V stage of puberty~* Post-menarche~* Hyperandrogenemic (total testosterone \> 0.4 ng/mL or free testosterone \> 35 pmol/L) with or without hirsutism~* Normal aspartate aminotransferase/alanine aminotransferase (AST/ALT) (AST \< 35 U/L, ALT \< 55 U/L)~* Hemoglobin \> 12 mg/dL or Hematocrit \> 36%~* Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia)~* Sexually active subjects must agree to abstain or use double barrier contraception during the study~* Subjects must agree not to take any other medications during the course of the study without approval by the study investigators~Exclusion Criteria:~* Abnormal screening labs (with the exception of the expected hormonal abnormalities inherent in hyperandrogenemia)~* Elevated AST/ALT (AST \> 35 U/L, ALT \> 55 U/L)~* Hemoglobin \<12 mg/dL or hematocrit \< 36%~* Weight \< 32 kg~* History of liver disease, peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer~* Pregnant or breastfeeding~* On medications known to affect the reproductive axis within 3 months of the study (including oral contraceptive pills, metformin, and spironolactone)~* On medications known or likely to inhibit or induce CYP1A2 or CYP3A4 (please see Restrictions on use of other drugs or treatments section below for common examples of such drugs)~* Are currently participating in another study or have been in one in the last 30 days.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Flutamide, estrace, progesterone (Type: EXPERIMENTAL): For flutamide, subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* in good health~* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.~* Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception Parts A, B and D~* BMI between 18 and 35 kg/m2 inclusive~* Fasting Triglycerides between 150 and 400mg/dL inclusive Part C~* Fasting Triglycerides between 200 and 400 mg/dL inclusive~* Fasting LDL-C between 70 and 160 mg/dL inclusive~* BMI between 18 and 40 kg/m2~Exclusion Criteria:~* significant history or clinical manifestation of metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator~* Confirmed (eg, 2 consecutive measurements) systolic blood pressure \>150 or \<90 mmHg, diastolic blood pressure \>90 or \<50 mmHg, and heart rate \>90 or \<40 beats per minute at Screening, Check-in, or prior to dosing on Day 1.~* History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.~* Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days or 5 half-lives (if known), whichever is longer, prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- STT-5058 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Early Vestibular Rehabilitation in Patients With Dizziness and Balance Disorders After Sport Concussion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dizziness or balance problems within 10 days of concussion~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Early Vestibular Rehabilitation (Type: EXPERIMENTAL): Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
- Standard of Care (Type: ACTIVE_COMPARATOR): Participants in this group will receive standard care as directed by their physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in Chronic Kid's (KiCK) Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject, parent, or guardian willing and able to give informed consent~* NRS for pain over the past 24 hours \>4 at baseline~* Chronic pain, which has been present for \>3 months, or persisting longer than is normal for the underlying diagnosis~* Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)~* Able to tolerate and cooperate with neurocognitive assessment~* Age 8-20 years old~Exclusion Criteria:~* If they are known or suspected to have drug addiction~* Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder~* Uncontrolled hypertension~* Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.~* Previous intolerance or allergic reaction to ketamine~* Pregnancy~* Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.~* Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine 0.25 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Ketamine 0.5 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Ketamine 1 mg/kg/dose (Type: EXPERIMENTAL): A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues